655. EXPANDING ACCESS TO KETAMINE THROUGH REFORMULATION
International Journal of Neuropsychopharmacology August 1, 2025 P. Glue
Abstract Background Ketamine, a rapidly acting antidepressant, requires dosing in clinic because of strong symptoms of dissociation and sedation after IV/IN dosing. This need for dosing in clinic limits capacity to treat patients with Treatment Resistant depression (TRD). We hypothesize that ketamine formulations that maximize ketamine’s first pass metabolism and delay absorption will have...